A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome

By sjmartinez • March 29, 2025

Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley RC, Larson SM, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley DM, Zeidan AM. A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome. Ann Hematol. 2025 Mar 28. doi: 10.1007/s00277-024-06081-4. Epub ahead of print. PMID: 40153010.

Tags: Acute myeloid leukemia, CTLA-4, durvalumab, First-in-human, Hematology/Oncology, MDS, PD-L1, Publications

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K,[...]

Biology, care, and outcomes of gestational breast cancers: a review

Duggirala N, Zhang S, Master A, Rao R, Kapoor NS, Bardia A, Lipsyc-Sharf M. Biology, care, and outcomes of gestational breast cancers: a review. Breast[...]

Yoo C, Ueno M, Klümpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park[...]